JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.

CDC reports that since June 2020 individuals infected with COVID-19 have largely been young adults in the 20-29 year age bracket. Moreover, younger adults appeared to be driving community transmission of COVID-19. 

JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19. A flurry of recent reports have described livedoid and necrotic eruptions in confirmed COVID-19 cases many of whom had severe disease.

Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August. It is now unequivocal, with the agency stating that for individuals without symptoms who have been in close contact with an infected person for at least 15 minutes: "You need a test."

Research from Oxford University suggests a potential pathogenic role for the chemokine CXCR3 and clonally restricted CD8+ T cells in the pathogenesis of psoriatic arthritis (PsA) based studies of PsA synovial fluid samples obtained by arthrocentesis from 11 patients with large-joint oligo PsA.

Patients with RA have up to a three-fold increased risk of mortality versus the general population, largely due to an increased incidence of premature CVD, such as atherosclerosis and heart failure. This excess risk is as high as that of patients with major CVD risk factors such as type 2 diabetes and is considered independent of traditional cardiovascular risk factors.